Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Neprilysin Inhibitors [MoA]

Known as: Neprilysin Inhibitors 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Neprilysin has become a focus of interest in cardiology, due to the impressive benefits of combining neprilysin inhibition and… Expand
  • table 1
  • table 2
Review
2017
Review
2017
Medication-induced angioedema is a bradykinin-mediated process that results from increased production or decreased degradation of… Expand
  • figure 1
  • table I
Review
2016
Review
2016
Neprilysin is acknowledged as a key player in neurohormonal regulation, a cornerstone of modern drug therapy in chronic heart… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2016
2016
La neprilisina ha pasado a ser uno de los centros de interes en cardiologia, debido a los impresionantes beneficios que se han… Expand
  • table 1
  • table 2
Highly Cited
2015
Highly Cited
2015
Neprilysin (also known as the neutral endopeptidase, EC 3.4.24.11) is a ubiquitous transmembrane and circulating protease with a… Expand
Review
2015
Review
2015
PURPOSE The aims of this article were to review the rationale behind the development of combined angiotensin receptor/neprilysin… Expand
  • figure 1
  • figure 2
  • figure 3
2011
2011
Background Progressive hypertension and deteriorating renal function are hallmarks of cardio-renal syndromes. Historically, the… Expand
  • figure 1